search
Back to results

IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy With Collagen Implant

Primary Purpose

Primary Open Angle Glaucoma

Status
Terminated
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
SENSIMED Triggerfish®
Sponsored by
Sensimed AG
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Primary Open Angle Glaucoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of POAG
  • Documented glaucomatous VF damage with mean defect (MD) > 3 dB
  • Progressing glaucomatous damage justifying a DSCI
  • Aged ≥18 years, of either sex
  • Not more than 4 diopters spherical equivalent on the study eye
  • Not more than 2 diopters cylinder equivalent on the study eye
  • Have given written informed consent, prior to any investigational procedures

Exclusion Criteria:

  • Corneal or conjunctival abnormality precluding contact lens adaptation
  • Severe dry eye syndrome
  • Patients with allergy to corneal anesthetic
  • Patients with contraindications for silicone contact lens wear
  • Patients not able to understand the character and individual consequences of the investigation
  • Participation in other clinical research within the last 4 weeks

Sites / Locations

  • Clinique Monchoisi, Unité du Glaucome

Outcomes

Primary Outcome Measures

Effect of DSCI on IOP fluctuation profile as recorded by Triggerfish® in patients with POAG.
The IOP fluctuation profile will be recorded by Triggerfish® in patients with POAG before DSCI 3 months after DSCI.

Secondary Outcome Measures

Effect of DSCI on the diurnal and nocturnal IOP fluctuation pattern
Diurnal and nocturnal IOP fluctuation pattern, wake/sleep and sleep/wake Triggerfish® slopes, Timing of Triggerfish® acrophase, Concomitant IOP-lowering topical drug use
Changes in visual field 3 months after DSCI
Change in the visual field
Safety and tolerability
Adverse events and serious adverse events collected throughout the duration of the study

Full Information

First Posted
March 20, 2012
Last Updated
May 19, 2015
Sponsor
Sensimed AG
Collaborators
Clinique Monchoisi
search

1. Study Identification

Unique Protocol Identification Number
NCT01561001
Brief Title
IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy With Collagen Implant
Official Title
24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Primary Open Angle Glaucoma Before and After Deep Sclerectomy With Collagen Implant
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Terminated
Study Start Date
April 2012 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
March 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sensimed AG
Collaborators
Clinique Monchoisi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary open angle glaucoma (POAG) is associated with inadequate drainage of the aqueous humor via the trabecular meshwork towards the systemic circulation. This may lead to an increase in IOP and may damage the optic nerve. The purpose of glaucoma management is to lower IOP in order to prevent progression of the optic neuropathy and subsequent visual loss. Firstline treatment usually includes IOP-lowering drug therapy. However, if IOP remains uncontrolled and/or the optic nerve damage progresses despite controlled IOP, surgery may be indicated. Deep sclerectomy with a collagen implant (DSCI) is a non-penetrating surgical procedure for the treatment of open angle glaucoma that allows the enhancement of the aqueous outflow. This forms the rationale to conduct this prospective, open label study to assess the 24-hour IOP fluctuation profile recorded with Triggerfish® in patients with POAG before and after DSCI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Open Angle Glaucoma

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
3 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
SENSIMED Triggerfish®
Intervention Description
Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
Primary Outcome Measure Information:
Title
Effect of DSCI on IOP fluctuation profile as recorded by Triggerfish® in patients with POAG.
Description
The IOP fluctuation profile will be recorded by Triggerfish® in patients with POAG before DSCI 3 months after DSCI.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Effect of DSCI on the diurnal and nocturnal IOP fluctuation pattern
Description
Diurnal and nocturnal IOP fluctuation pattern, wake/sleep and sleep/wake Triggerfish® slopes, Timing of Triggerfish® acrophase, Concomitant IOP-lowering topical drug use
Time Frame
3 months
Title
Changes in visual field 3 months after DSCI
Description
Change in the visual field
Time Frame
3 months
Title
Safety and tolerability
Description
Adverse events and serious adverse events collected throughout the duration of the study
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of POAG Documented glaucomatous VF damage with mean defect (MD) > 3 dB Progressing glaucomatous damage justifying a DSCI Aged ≥18 years, of either sex Not more than 4 diopters spherical equivalent on the study eye Not more than 2 diopters cylinder equivalent on the study eye Have given written informed consent, prior to any investigational procedures Exclusion Criteria: Corneal or conjunctival abnormality precluding contact lens adaptation Severe dry eye syndrome Patients with allergy to corneal anesthetic Patients with contraindications for silicone contact lens wear Patients not able to understand the character and individual consequences of the investigation Participation in other clinical research within the last 4 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
André Mermoud, MD
Organizational Affiliation
Clinique Monchoisi, Unité du Glaucome
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinique Monchoisi, Unité du Glaucome
City
Lausanne
ZIP/Postal Code
1006
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy With Collagen Implant

We'll reach out to this number within 24 hrs